Skip to main content

Feb 12th Webinar: Denali Transport Vehicle (TV) Technology: DNL310 (ETV:IDS) Ph1/2 Cohort A Interim Data in Hunter Syndrome Patients

Denali Therapeutics
  • Home
  • Scientific Approach
    • Genetic Pathway Potential
    • Engineering Brain Delivery
    • Biomarker-Driven Development
    • Publications
  • Pipeline
  • Patient Community
    • HUNTER SYNDROME (MPS II)
    • SANFILIPPO SYNDROME (MPS III A)
    • PARKINSON’S DISEASE
    • AMYOTROPHIC LATERAL SCLEROSIS (ALS)
    • FRONTOTEMPORAL DEMENTIA (FTD)
    • ALZHEIMER’S DISEASE
    • EXPANDED ACCESS POLICY (EAP)
  • Investor & Media Relations
    • Press Releases
    • Events
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
  • Leadership
  • Partnering
  • Careers
    • Job openings
    • STEM Outreach Overview
    • Student Internships
    • Postdoc Program
  • Contact

 

 

 

Contact Us

161 Oyster Point Blvd.
South San Francisco, CA
94080

 

By clicking submit you agree to our terms of service and privacy policy.

Join Us

CONTACT US

161 Oyster Point Blvd- South San Francisco, CA 94080

© 2025 Denali Therapeutics

  • Privacy Policy
  • Terms of Use

©2020 Denali Therapeutics | 161 Oyster Point Boulevard, South San Francisco, CA 94080

  • Privacy Policy
  • Terms of Use